Hemosiderosis: Difference between revisions
mNo edit summary |
No edit summary |
||
Line 13: | Line 13: | ||
}} | }} | ||
{{Hemosiderosis}} | {{Hemosiderosis}} | ||
{{CMG}} | {{CMG}} [[Roghayeh Marandi]] | ||
{{SK}} Idiopathic pulmonary hemosiderosis; IPH; hemosiderin accumulation; Pulmonary hemosiderosis; Pulmonary haemosiderosis; Essential brown induration of lung; Brown induration of lung; Ceelen-Gellerstedt syndrome | {{SK}} Idiopathic pulmonary hemosiderosis; IPH; hemosiderin accumulation; Pulmonary hemosiderosis; Pulmonary haemosiderosis; Essential brown induration of lung; Brown induration of lung; Ceelen-Gellerstedt syndrome |
Latest revision as of 08:15, 28 September 2020
Hemosiderosis | |
ICD-9 | 516.1 |
---|---|
OMIM | 178550 |
DiseasesDB | 29717 |
Hemosiderosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hemosiderosis On the Web |
American Roentgen Ray Society Images of Hemosiderosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Roghayeh Marandi
Synonyms and keywords: Idiopathic pulmonary hemosiderosis; IPH; hemosiderin accumulation; Pulmonary hemosiderosis; Pulmonary haemosiderosis; Essential brown induration of lung; Brown induration of lung; Ceelen-Gellerstedt syndrome
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hemosiderosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies